Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Malignant Skin Neoplasm
- Metastatic Malignant Skin Neoplasm
Interventions
- DRUG: Atezolizumab
- DRUG: Avelumab
- BIOLOGICAL: Cemiplimab
- BIOLOGICAL: Durvalumab
- BIOLOGICAL: Nivolumab
- BIOLOGICAL: Pembrolizumab
- OTHER: Quality-of-Life Assessment
- OTHER: Short-Term Fasting
- BIOLOGICAL: Dostarlimab
- BIOLOGICAL: Retifanlimab
- BIOLOGICAL: Toripalimab
- BIOLOGICAL: Tislelizumab
Sponsor
University of Southern California
Collaborators